Literature DB >> 24070777

The toxicity of nitrofuran compounds on melanoma and neuroblastoma cells is enhanced by Olaparib and ameliorated by melanin pigment.

Ewan M McNeil1, Ann-Marie Ritchie, David W Melton.   

Abstract

Nitrofurans are commonly used for the treatment of trypanosomal diseases including Chagas disease. More recently, following the fortuitous discovery that nifurtimox was clinically active against neuroblastoma, nitrofuran compounds are being investigated for activity against cancer. Herein, we show that nitrofuran compounds are similarly potent to human malignant melanoma and neuroblastoma cells. Furthermore, a recently discovered nitrofuran compound, NFN1, was 50- to 175-fold more potent than nifurtimox against human melanoma and neuroblastoma cell lines. As nitrofuran compounds are known to act as pro-drugs, producing DNA-damaging reactive intermediates upon activation, we investigated the DNA repair pathways involved. We show that, contrary to research in Escherichia coli, the Nucleotide Excision Repair pathway is not required to repair nitrofuran-induced DNA damage in mammalian cells. Instead, we show that inhibiting repair of single-strand DNA breaks with the poly(ADP-ribose) polymerase (PARP) inhibitor, Olaparib, enhances nitrofuran toxicity in melanoma and neuroblastoma cells. We propose that this is due to mammalian cells utilising Type 2 nitroreductases for nitrofuran activation producing Reactive Oxygen Species which cause DNA damage that is repaired by the Single Strand Break Repair and/or Base Excision Repair pathways, whereas in bacteria and trypanosomes, Type 1 nitroreductases are also utilised resulting in different DNA lesions. In addition we show that, consistent with Reactive Oxygen Species being formed upon nitrofuran activation and the ability of melanin to absorb Reactive Oxygen Species, production of melanin in melanoma cells offers some protection from NFN1- and hydrogen peroxide-induced toxicity. Our data suggest that combinations of Olaparib and nitrofuran compounds may be advantageous for the treatment of melanoma and neuroblastoma, but that the protection offered to melanoma cells by their melanin pigment must be taken into account.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ERCC1-XPF; Melanin; Melanoma; Neuroblastoma; Nitrofuran; PARP inhibitor

Mesh:

Substances:

Year:  2013        PMID: 24070777     DOI: 10.1016/j.dnarep.2013.08.017

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  5 in total

1.  Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.

Authors:  Karin Melanie Cabanillas Stanchi; Gernot Bruchelt; Rupert Handgretinger; Ursula Holzer
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

2.  Blueberries inhibit cyclooxygenase-1 and cyclooxygenase-2 activity in human epithelial ovarian cancer.

Authors:  Wumei Lin; Zhigang Li
Journal:  Oncol Lett       Date:  2017-04-25       Impact factor: 2.967

3.  PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

Authors:  V Colicchia; M Petroni; G Guarguaglini; F Sardina; M Sahún-Roncero; M Carbonari; B Ricci; C Heil; C Capalbo; F Belardinilli; A Coppa; G Peruzzi; I Screpanti; P Lavia; A Gulino; G Giannini
Journal:  Oncogene       Date:  2017-04-10       Impact factor: 9.867

4.  Environmental persistence, hazard, and mitigation challenges of nitroaromatic compounds.

Authors:  Jyoti Tiwari; Prashant Tarale; Saravanadevi Sivanesan; Amit Bafana
Journal:  Environ Sci Pollut Res Int       Date:  2019-08-06       Impact factor: 4.223

5.  The Integrative Analysis Identifies Three Cancer Subtypes and Stemness Features in Cutaneous Melanoma.

Authors:  Xiaoran Wang; Qi Wan; Lin Jin; Chengxiu Liu; Chang Liu; Yaqi Cheng; Zhichong Wang
Journal:  Front Mol Biosci       Date:  2021-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.